BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
Vandana SinghWed, March 4, 2026 at 1:00 PM UTC
0
On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’s supplemental application for Palynziq (pegvaliase-pqpz), a treatment for phenylketonuria (PKU) in adolescents aged 12 and older.
FDA’s Expanded Approval
The FDA approved BioMarin’s supplemental Biologics License Application for Palynziq, making it the only enzyme substitution therapy approved for PKU management in pediatric patients aged 12 and older.
Phenylketonuria is a rare inherited disorder that causes an amino acid called phenylalanine (phe) to build up in the body.
The approval is based on the results from the Phase 3 PEGASUS study, which demonstrated statistically significant reductions in blood phenylalanine levels compared to diet alone.
Don't Miss:
Explore the Fire-Safe Energy Storage Company With $185M in Contracted Revenue
Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In at $0.85/Share
Individuals in the Palynziq arm showed a significant mean reduction from baseline in blood Phe levels at Week 72 compared to those in the diet-only arm.
The company is also pursuing approval from the European Medicines Agency to expand treatment options for adolescents in the EU.
Technical Analysis
The stock is currently trading 4.5% below its 20-day simple moving average (SMA) and 8.2% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have decreased by approximately 19%, and they are currently positioned closer to their 52-week lows than highs, reflecting a challenging market environment.
Advertisement
Trending: Own the Characters, Not Just the Content: Inside a Fast-Growing Pre-IPO IP Company
The RSI is at 50.00, suggesting a neutral position, while the MACD is at -0.10, below its signal line at 0.05, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
Key Resistance: $73.50
Key Support: $50.00
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $88.80. Recent analyst moves include:
Canaccord Genuity: Buy (Raises Target to $104.00) (Feb. 26)
Bernstein: Outperform (Raises Target to $94.00) (Feb. 25)
Guggenheim: Buy (Lowers Target to $86.00) (Feb. 25)
Read Next:
1.5 Million Users Are Already Working Inside This AI Platform — Investors Can Still Get In
Blue-chip art has historically outpaced the S&P 500 since 1995, and fractional investing is now opening this institutional asset class to everyday investors.
Photo by Tada Images via Shutterstock
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga:
APPLE (AAPL): Free Stock Analysis Report
TESLA (TSLA): Free Stock Analysis Report
This article BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients originally appeared on Benzinga.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Source: “AOL Money”
